Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure
- PMID: 15905673
- PMCID: PMC1373680
- DOI: 10.1097/01.aids.0000171406.53737.f9
Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure
Abstract
Context: The impact of HIV infection and exposure to antiretroviral therapy on the development of subclinical atherosclerosis is incompletely understood.
Objective: To compare intima-media thickness (IMT) of the carotid artery between HIV-infected subjects receiving protease inhibitor-containing regimens and subjects not receiving these regimens and to compare differences in the IMT of the carotid artery between HIV-infected subjects and HIV-uninfected subjects.
Methods: A prospective matched cohort study in university-based outpatient clinics. Groups of three individuals (triads) matched on the following characteristics were enrolled: age, sex, race/ethnicity, smoking status, blood pressure and menopausal status. Group 1, HIV-infected subjects with continuous use of protease inhibitor (PI) therapy for > or = 2 years; group 2, HIV-infected subjects without prior PI use; and group 3: HIV-uninfected. Ultrasonographers at six sites sent standardized ultrasound images to a central reading site for carotid IMT measurements. Carotid IMT was compared within the HIV-infected groups (1 and 2) and between the HIV-infected and uninfected groups in a matched analysis.
Results: One hundred and thirty-four individuals were enrolled in 45 triads. The median IMT in groups 1, 2 and 3 was 0.690, 0.712 and 0.698 mm, respectively. There were no statistically significant differences in IMT between groups 1 and 2, or in the combined HIV groups compared with the HIV uninfected group. Significant predictors of carotid IMT in a multivariate model included high-density lipoprotein (HDL) cholesterol, the interaction of HDL cholesterol and triglycerides, age and body mass index.
Conclusions: We found no association between PI inhibitor exposure or HIV infection and carotid IMT.
Figures
Comment in
-
Carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients.AIDS. 2005 Nov 4;19(16):1936-7. doi: 10.1097/01.aids.0000189564.87600.04. AIDS. 2005. PMID: 16227814 No abstract available.
References
-
- Mulligan K, Grunfeld C, Tai VW, Algran H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immun Defic Syndr. 2000;23:35–43. - PubMed
-
- Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63–F70. - PubMed
-
- Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med. 1999;246:567–575. - PubMed
-
- Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS. 1998;12:F51–F58. - PubMed
-
- Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–2099. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
